The molecular genetic landscape of prostate cancer and its association with thrombosis
Urology reports (St. - Petersburg) · 22.10.2026 · 16 (3) · 403-415
DOI: 10.17816/uroved705414 ↗Kurz gefasst
Fachartikel in der Zeitschrift Urology reports (St. - Petersburg), online erschienen am 22.10.2026. Verfasst von Anatoly Yu. Popov und 9 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Prostate cancer (PCa) remains one of the leading causes of cancer morbidity and mortality in men. In recent years, significant progress has been made in understanding the molecular genetic heterogeneity of PCa, which determines the aggressiveness of the disease, prognosis, and response to therapy. In parallel, evidence is accumulating that the oncological process and its treatment, especially androgen deprivation therapy, are accompanied by an increased risk of venous thromboembolism (VTE). This review examines the association between the PCa molecular landscape and thrombotic complications. We analyzed publications in PubMed, Scopus, Web of Science, and ResearchGate, mainly for 2010–2025. The general mechanisms of the cancer–thrombosis link were considered, including expression of tissue factor, cancer procoagulant, pro-inflammatory cytokines, platelet activation, neutrophil extracellular traps, and suppression of fibrinolysis. The key molecular genetic subtypes of PCa are described in detail: defects in homologous recombination repair genes (BRCA1/2, ATM, CHEK2, PALB2), TMPRSS2-ERG fusion, PTEN deletion, TP53 mutations, and androgen receptor amplification. Aggressive tumor subtypes have been shown to be indirectly associated with a higher risk of VTE through rapid progression, metastasis, intensive treatment, and deterioration of the patient’s general condition. The contribution of androgen deprivation therapy to hypercoagulation is discussed. Interdisciplinary clinical guidelines and an algorithm of actions for geneticists, oncologists, chemotherapists, vascular surgeons, and anesthesiologists and critical care physicians are presented. Particular attention is paid to practical aspects: VTE risk stratification, choice of anticoagulant prophylaxis, and perioperative management. The role of molecular profiling in identifying patients at high thrombotic risk is emphasized. Unresolved problems are identified: the lack of direct biomarkers of tumor thrombogenicity, the need for integrated VTE risk scales taking into account genomic data, and issues of personalization of thromboprophylaxis. It is concluded that a personalized multidisciplinary approach combining PCa molecular profiling, thrombotic risk assessment, and timely VTE prevention is needed.
Zitieren
APA
Popov, A. Y., Monakov, D. M., Baitman, T. P., Simonov, A. D., Borukaev, A. Y., Makarov, V. A., Paichadze, A. A., Dondokova, A. T., Gritskevich, A. A., & Zhukov, N. V. (2026). The molecular genetic landscape of prostate cancer and its association with thrombosis. Urology reports (St. - Petersburg), 16(3), 403-415. https://doi.org/10.17816/uroved705414
Vancouver
Popov AY, Monakov DM, Baitman TP, Simonov AD, Borukaev AY, Makarov VA, et al. The molecular genetic landscape of prostate cancer and its association with thrombosis. Urology reports (St. - Petersburg). 2026;16(3):403-415. doi:10.17816/uroved705414
BibTeX
@article{Popov2026,
author = {Popov, Anatoly Yu. and Monakov, Dmitry M. and Baitman, Tatiana P. and Simonov, Anton D. and Borukaev, Andemirkan Yu. and Makarov, Vladislav A. and Paichadze, Anna A. and Dondokova, Aryuna T. and Gritskevich, Alexander A. and Zhukov, Nikolay V.},
title = {The molecular genetic landscape of prostate cancer and its association with thrombosis},
journal = {Urology reports (St. - Petersburg)},
year = {2026},
volume = {16},
number = {3},
pages = {403--415},
doi = {10.17816/uroved705414}
}
EUVIMED